For research use only. Not for therapeutic Use.
Mito-apocynin (C11), an orally active mitochondria-targeted triphenylphosphonium (TPP)-based compound, is synthesized by conjugating the Apocynin moiety with a TPP+ cation. Mito-apocynin (C11) selectively targets mitochondria, and shows neuroprotective effect. Mito-apocynin (C11) prevents hyposmia and corrects deficits in motor function[1].
Mito-apocynin-C11 (3 mg/kg; oral gavage; 3x/wk from 3 months of age until 15 months) markedly improves the coordinated motor function and olfactory function in LRRK2R1441G mice[1].
| Catalog Number | I016212 |
| CAS Number | 1254044-38-6 |
| Synonyms | 11-(4-hydroxy-3-methoxybenzoyl)oxyundecyl-triphenylphosphanium;bromide |
| Molecular Formula | C37H44BrO4P |
| Purity | ≥95% |
| InChI | InChI=1S/C37H43O4P.BrH/c1-40-36-30-31(26-27-35(36)38)37(39)41-28-18-7-5-3-2-4-6-8-19-29-42(32-20-12-9-13-21-32,33-22-14-10-15-23-33)34-24-16-11-17-25-34;/h9-17,20-27,30H,2-8,18-19,28-29H2,1H3;1H |
| InChIKey | VWMXQDPFRLJGQR-UHFFFAOYSA-N |
| SMILES | COC1=C(C=CC(=C1)C(=O)OCCCCCCCCCCC[P+](C2=CC=CC=C2)(C3=CC=CC=C3)C4=CC=CC=C4)O.[Br-] |
| Reference | [1]. Dranka BP, et al. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson’s disease. Neurosci Lett. 2014 Nov 7;583:159-64. |
